PALO ALTO, Calif.--(BUSINESS WIRE)--Cromatic, a full-stack digital platform for outsourced life sciences research, today announced it has closed $5.3 million in funding. LifeX Ventures and AgFunder ...

The lab market in suburban Maryland, like its peers across the country, has been battling a supply-demand imbalance for a few years now. A surge in construction followed by a drop in venture capital ...

German industrial giant Siemens AG said today it will pay $5.1 billion to acquire the life sciences data startup Dotmatics in an effort to expand its artificial intelligence offerings. The company ...

Discover Manthan 2026, a premier symposium by VASUs Foundation aimed at elevating India's role in life sciences research and ...

How is software-enablement — connected devices and artificial intelligence — reshaping how products are conceived, developed, ...

Here are seven of ZS's strengths, according to the report: The IDC MarketScape also noted, "ZS offers a wide range of GenAI capabilities across the clinical trial value chain, including site selection ...

In life sciences research and development (R&D), to truly enhance fragmented data, it must be both accessible and relevant. LabVantage BioTech360 serves as the platform that guarantees valuable ...

Strategic leadership additions deepen scientific rigor and quality systems of OFD Life Sciences to scale innovation in biopharma, med tech, and health markets "Together, Steven and Ian bring nearly 50 ...

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the top long-term biotechnology stocks to buy. On October 27, SELLAS Life Sciences (NASDAQ:SLS) announced the immediate exercise of warrants for ...

An investigational, novel combination therapy, consisting of an N-methyl-D-aspartate receptor-modulating drug (ketamine) delivered intravenously (IV) in combination with manualized relapse prevention ...

Life sciences industries are driving high growth in economic output, jobs and business creation in New Hampshire. However, New Hampshire could lose momentum on the growth of these ground-breaking ...

Over the past four years, private equity (PE) firms that invested in life science assets have faced a difficult reality. While many investors still debate whether some sectors of the market are in a ...